相关实验视频

Updated: May 10, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

针对miR-103a-3p/IGFBP5轴:对于胃癌进展的潜在治疗策略

Junrui Zhang¹, Yue Qiu², Fubin Ma³

¹The First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, 730000, China.

Discover oncology

|April 22, 2025

概括

在胃癌中,microRNA miR-103a-3p被上调,促进瘤的进展. 针对miR-103a-3p/IGFBP5轴为这种致命疾病提供了潜在的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一种遗传学.

背景情况:

胃癌导致全球显著的死亡率,治疗选择有限.
微RNA是癌症的关键调节者,影响癌症的增殖,迁移,入侵和亡.
在胃癌发病过程中miR-103a-3p的具体作用在很大程度上是未知的.

研究的目的:

研究胃癌中miR-103a-3p的表达和功能.
确定分子点和机制,以确定miR-103a-3p在胃癌进展中的作用.
评估miR-103a-3p/IGFBP5轴作为潜在的治疗标和预后标记.

主要方法:

定量实时PCR用于评估胃癌组织和相邻的非癌性组织中的miR-103a-3p表达.
在体外功能测试 (扩散,入侵,迁移) 确定miR-103a-3p.p的作用.
生物信息分析和 luciferase 记者测定用于识别和验证 miR-103a-3p 目标.
用IGFBP5过度表达的救援实验证实其在调解miR-103a-3p效应中的作用.

主要成果:

与非癌性组织相比,胃癌组织中的miR-103a-3p表达显著增加.
刺激miR-103a-3p增强了胃癌细胞的扩散,入侵和迁移.
胰岛素样生长因子结合蛋白5 (IGFBP5) 被确定为miR-103a-3p的直接标.
过度表达IGFBP5可以抵消miR-103a-3p的前瘤性作用.

结论:

在促进胃癌进展方面,miR-103a-3p/IGFBP5轴起着至关重要的作用.
在胃癌中,miR-103a-3p通过向IGFBP5.5而作为瘤性微RNA起作用.
这个轴代表了胃癌的有前途的治疗标和预后生物标志物.

关键词:

胃癌是什么?胃癌是什么?在IGFBP5中使用.预测预测预测预测的时间.在 miR-103a-3p 中使用.

更多相关视频

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...